TOG Review (RCOG Journal)
MRCOG Part 2
Urogynaecology and Pelvic Floor Problems
Vaginal mesh in prolapse surgery
Key Statistics
- 46% vs 18% — Anatomic failure: Biological vs synthetic mesh (p=0.015)
- 15.8% — Lifetime risk repeat POP surgery (UK, n=47,000)
- 12% — Mesh complication rate at 2yr, PROSPECT (n=1352)
Don't-miss facts
-
Only Type 1 macroporous (>75 µm) monofilament polypropylene mesh is used for current POP repair (Amid classification)
-
ProteGen® (1996) approved via FDA 510(k) pathway without dedicated transvaginal safety trials – root of the regulatory controversy
-
FDA reclassified transvaginal POP mesh class II→III in Jan 2016 after declaring adverse events “not rare” (2011)
-
Maher 2016 Cochrane (37 RCTs): mesh ↓recurrence but ↑combined repeat surgery (RR 2.40), ↑de novo SUI (RR 1.39), ↑bladder injury (RR 3.92) – no evidence to support routine use
-
PROSPECT (n=1352): no benefit from mesh/graft augmentation of primary repair at 1–2yr; synthetic mesh complications 12% at 2yr
-
Biological mesh: significantly higher anatomic failure than synthetic mesh (46% vs 18%, P=0.015)
-
UK lifetime risk of repeat POP surgery after native tissue repair = 15.8% (lower than the 30–50% historically quoted)
-
Informed consent (shared decision making) is the key ethical issue; mesh use carries greater litigation risk than native tissue repair
Evidence & regulatory timeline
1996: FDA 510(k) approval (ProteGen®) 2011: FDA – adverse events “not rare” 2016: class II→III reclassification
2017: PROSPECT – no benefit at 1–2yr
Abbreviation Key
- POP — pelvic organ prolapse
- PROSPECT — PROlapse Surgery: Pragmatic Evaluation and randomised Controlled Trials
- SUI — stress urinary incontinence
- POP-SS — Pelvic Organ Prolapse Symptom Score
- FDA — US Food and Drug Administration
- POP-Q — Pelvic Organ Prolapse Quantification system
- MHRA — Medicines and Healthcare products Regulatory Agency
- RCT — randomised controlled trial
- NICE — National Institute for Health and Care Excellence
- RR — relative risk
- RCOG — Royal College of Obstetricians and Gynaecologists
- CI — confidence interval
- BSUG — British Society of Urogynaecology
- MAUDE — Manufacturer and User Device Experience database
- BAUS — British Association of Urological Surgeons
- GMC — General Medical Council
- IUGA — International Urogynecological Association
- HES — hospital episode statistics
- SCENIHR — Scientific Committee on Emerging and Newly Identified Health Risks
Source: Campbell P, Jha S, Cutner A. Vaginal mesh in prolapse surgery. The Obstetrician & Gynaecologist 2018;20:49–56. doi:10.1111/tog.12454
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).